Abstract:Background: Chronic hepatitis B virus (HBV) infection affects around 250 million people worldwide, causing approximately 887,000 deaths annually, primarily owing to cirrhosis and hepatocellular carcinoma (HCC). The current approved treatments for chronic HBV infection, such as interferon and nucleos(t)ide analogs, have certain limitations as they cannot completely eradicate covalently closed circular DNA (cccDNA). Considering that HBV replication relies on host transcription factors, focusing on host factors in the HBV genome may provide insights into new therapeutic targets against HBV. Therefore, understanding the mechanisms underlying viral persistence and hepatocyte pathogenesis, along with the associated host factors, is crucial. In this study, we investigated novel therapeutic targets for HBV infection by identifying gene and pathway networks involved in HBV replication in primary human hepatocytes (PHHs). Importantly, our study utilized cultured primary hepatocytes, allowing transcriptomic profiling in a biologically relevant context and enabling the investigation of early HBV-mediated effects. Methods: PHHs were infected with HBV virion particles derived from HepAD38 cells at 80 HBV genome equivalents per cell (Geq/cell). For transcriptomic sequencing, PHHs were harvested 1, 2-, 3-, 5-, and 7 days post-infection (dpi). After preparing the libraries, clustering and sequencing were conducted to generate RNA-sequencing data. This data was processed using Bioinformatics tools and software to analyze DEGs and obtain statistically significant results. Furthermore, qRT-PCR was performed to validate the RNA-sequencing results, ensuring consistent findings. Results: We observed significant alterations in the expression patterns of 149 genes from days 1 to 7 following HBV infection (R2 > 0.7, q < 0.05). Functional analysis of these genes identified RNA-binding proteins involved in mRNA metabolism and the regulation of alternative splicing during HBV infection. Results from qRT-PCR experiments and the analysis of two validation datasets suggest that RBM14 and RPL28 may serve as potential biomarkers for HBV-associated HCC. Conclusions: Transcriptome analysis of gene expression changes during HBV infection in PHHs provided valuable insights into chronic HBV infection. Additionally, understanding the functional involvement of host factor networks in the molecular mechanisms of HBV replication and transcription may facilitate the development of novel strategies for HBV treatment.

Influence of host factors on the antiviral treatment efficacy in chronic hepatitis C

Cytokines and Chemokines in HBV Infection

Clinical efficacy and safety of ravidavir-based antiretroviral regimen in treatment of patients with chronic hepatitis C

Study on the Efficacy and Related Factors of Antiviral Therapy in Chronic Hepatitis B

HCV genotyping and host genotyping: what role will they play in the antiviral treatment

Factors Affecting the Efficacy of Antiviral Treatment on Patients with HCV-related Cirrhosis

Research advances in cytokines in the treatment of chronic hepatitis B

Impact of Virus Genotype on Interferon Treatment of Patients with Chronic Hepatitis C: a Multicenter Controlled Study.

Antiviral Action Of Interferon-Alpha Against Hepatitis C Virus Replicon And Its Modulation By Interferon-Gamma And Interleukin-8

Current perspectives on the efficacy and mechanisms of combination therapy for chronic hepatitis B virus

Interferon and interferon-stimulated genes in HBV treatment

Optimal management and outlook for antiviral therapy of chronic HBV infection

Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy

[Research Advances on Treatment of Hepatitis C Infection Based on RNA Interference and Microrna Modulation].

Potential Drug Targets Against Hepatitis B Virus Based on Both Virus and Host Factors.

Current trends and advances in antiviral therapy for chronic hepatitis B

Mechanisms Underlying the Compromised Clinical Efficacy of Interferon in Clearing HBV

Evolution of viral RNA in a Chinese patient to interferon/ribavirin therapy for hepatitis C

Host Genotyping and Direct-Acting Antiviral Agents: a New Era of Individualized Treatment Strategy for Hepatitis C

Analysis of host factor networks during hepatitis B virus infection in primary human hepatocytes

Antiviral Therapy for Chronic Hepatitis B: Current Status and Prospects